Therapeutic Response Statement (Sensitivity) Deprecated
This therapeutic response statement Supports the relationship that ER positive and PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole as a treatment option for extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.
This statement is based on a regulatory approval from the Health Service Executive:
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2014-11-01 | Health Service Executive | Indication approved for reimbursement. |